DJIA 16,204.97 -211.61 -1.29%
NASDAQ 4,363.14 -146.42 -3.25%
S&P 500 1,880.05 -35.40 -1.85%
market minute promo

Merck & Co., Inc. (NYSE: MRK)

company name or ticker
Company Photos
(Click to zoom)

Last Week's Best Healthcare ETF

It was another rough week for the healthcare sector, but this healthcare ETF performed the best.

Grading Gilead Sciences' Performance in 2015

The highs and lows (but mostly highs) from Gilead Sciences’ earnings call.

1 Company Gilead Sciences Should Consider Buying Right Now

Given that it's flush with cash but shaky on growth, an acquisition could be in Gilead Sciences future. This company stands out as the most obvious target.

ImmunoGen/Merck Collaborate for Ovarian Cancer Study

Amgen's Blincyto and Repatha Positive in Phase III Studies

Gilead Sciences 2016 Guidance: Sandbagging Wall Street Again?

The company's track record of beating forecasts could continue again this year.

Updating My Price Target On Gilead Sciences For 2016

A Checkup On A Big Healthcare ETF

This Week In Pharma: Questions For Experts On Merck's ZEPATIER, Portola's Betrixaban

5 Stocks We're Buying Again

Here's what five Fools are buying while the market is down.
See More Articles...